Academia Sinica yesterday approved the resignation of distinguished research fellow Chen Ching-shih (陳慶士) after news of research misconduct in eight of his published papers was made public by the Ohio State University, where he previously served as a cancer researcher.
Academia Sinica said in a statement that it is sorry to hear about the incident, but added that Chen’s misconduct occurred before he became head of Academia Sinica’s Institute of Biological Chemistry in August 2014.
The institution’s Research Ethics Committee would still look into work he performed while serving at the academy, the statement added.
Chen’s resignation from the Academia Sinica comes after academic journal Science and the university issued separate reports on Friday regarding the findings of research misconduct that led to his resignation as a cancer researcher from the university last year.
The reports said the investigation found Chen had “intentionally committed research misconduct” in 14 instances in eight journal articles, and was guilty of “deviating from the accepted practices of image handling and figure generation and intentionally falsifying data.”
Chen admitted to the charges and resigned in September last year, the university said.
The university said it has requested an “immediate retraction” of the papers, published between 2006 and 2014, that contain the fabricated data.
However, the implications of the misconduct go beyond unreliable academic papers, as Chen’s work had raised millions of US dollars in funding and led to multiple patents and the establishment of two compounds in clinical trials.
The university said it immediately shut down a clinical trial of one of Chen’s anti-cancer agents that Arno Therapeutics Inc had been conducting after obtaining exclusive rights to test the agents.
A spokesperson for the company said that issues with Chen’s papers had “zero impact” on its drug development efforts, Science said.
The university said it “hired an external consultant who validated that Chen’s research misconduct did not affect the Arno licensed compounds developed in his lab.”
“Patient safety was never compromised,” the university’s statement said.
The university said it has forwarded the investigation to federal authorities, meaning Chen could continue to be investigated for his actions.
Academia Sinica first became aware of the matter about a year ago, but it had limited access to Chen’s questionable articles because the university did not reveal its investigation on its Web site until Friday, Academia Sinica Central Academic Advisory Committee executive secretary Henry Sun (孫以瀚) said yesterday.
This is the worst punishment a Taiwanese academic has ever received from a foreign institution, dealing a heavy blow to the nation’s image in international academia, Sun said.
Sun quoted Chen as saying that his laboratory staff “beautified” data to make their research look better, and that he was responsible for lax supervision.
Yesterday morning, Chen’s profile was accessible on the Institute of Biological Chemistry’s Web site, but it was later taken down after Chen tendered his verbal resignation to Academia Sinica president James Liao (廖俊智).
Meanwhile, China Medical University, where Chen in February temporarily served as the director of its Institute of New Drug Development, yesterday said it is unclear about the matter and is collecting information about the case.
Before Chen returned to Taiwan to serve as director of the Institute of Biological Chemistry in August 2014 — a position he held until August last year — he had taught at the Ohio State University’s College of Pharmacy, the University of Rhode Island and the University of Kentucky.
Specializing in medicinal chemistry, cancer studies, biological chemistry and translational medicine, Chen has received research awards from the US Prostate Cancer Foundation and the Hearst Foundation, and is a fellow at the American Association for the Advancement of Science.
In April last year, he and National Cheng Kung University researchers found a relation between vitamin E and cancer prevention, and created an anti-tumor agent that is 20 times more efficient than previous ones, which was then considered a potential opportunity to develop a new anti-cancer drug.
GEARING UP: An invasion would be difficult and would strain China’s forces, but it has conducted large-scale training supporting an invasion scenario, the report said China increased its military pressure on Taiwan last year and took other steps in preparation for a potential invasion, an annual report published by the US Department of Defense on Wednesday showed. “Throughout 2023, Beijing continued to erode longstanding norms in and around Taiwan by employing a range of pressure tactics against Taiwan,” the report said, which is titled “Military and Security Developments Involving the People’s Republic of China (PRC) 2024.” The Chinese People’s Liberation Army (PLA) “is preparing for a contingency to unify Taiwan with the PRC by force, if perceived as necessary by Beijing, while simultaneously deterring, delaying or denying
‘LAGGING BEHIND’: The NATO secretary-general called on democratic allies to be ‘clear-eyed’ about Beijing’s military buildup, urging them to boost military spending NATO Secretary-General Mark Rutte mentioning China’s bullying of Taiwan and its ambition to reshape the global order has significance during a time when authoritarian states are continuously increasing their aggression, the Ministry of Foreign Affairs (MOFA) said yesterday. In a speech at the Carnegie Europe think tank in Brussels on Thursday, Rutte said Beijing is bullying Taiwan and would start to “nibble” at Taiwan if Russia benefits from a post-invasion peace deal with Ukraine. He called on democratic allies to boost defense investments and also urged NATO members to increase defense spending in the face of growing military threats from Russia
PEACEFUL RESOLUTION: A statement issued following a meeting between Australia and Britain reiterated support for Taiwan and opposition to change in the Taiwan Strait Canada should support the peaceful resolution of Taiwan’s destiny according to the will of Taiwanese, Canadian lawmakers said in a resolution marking the second anniversary of that nation’s Indo-Pacific strategy on Monday. The Canadian House of Commons committee on Canada-Chinese relations made the comment as part of 34 recommendations for the new edition of the strategy, adding that Ottawa should back Taiwan’s meaningful participation in international organizations. Canada’s Indo-Pacific Strategy, first published in October 2022, emphasized that the region’s security, trade, human rights, democracy and environmental protection would play a crucial role in shaping Canada’s future. The strategy called for Canada to deepen
TECH CONFERENCE: Input from industry and academic experts can contribute to future policymaking across government agencies, President William Lai said Multifunctional service robots could be the next new area in which Taiwan could play a significant role, given its strengths in chip manufacturing and software design, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) chairman and chief executive C.C. Wei (魏哲家) said yesterday. “In the past two months, our customers shared a lot of their future plans with me. Artificial intelligence [AI] and AI applications were the most talked about subjects in our conversation,” Wei said in a speech at the National Science and Technology Conference in Taipei. TSMC, the world’s biggest contract chipmaker, counts Nvidia Corp, Advanced Micro Devices Inc, Apple Inc and
RSS